MLICM
RCUS icon

Metropolitan Life Insurance Company (MetLife)’s Arcus Biosciences RCUS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,870
Closed -$54.2K – 1649
2024
Q1 		$54.2K Sell
2,870
-425
-13% -$7.35K ﹤0.01% 1366
2023
Q4 		$62.9K Hold
3,295
– – ﹤0.01% 1320
2023
Q3 		$59.1K Buy
3,295
+514
+18% +$10.3K ﹤0.01% 1308
2023
Q2 		$56.5K Hold
2,781
– – ﹤0.01% 1351
2023
Q1 		$50.7K Sell
2,781
-358
-11% -$6.84K ﹤0.01% 1384
2022
Q4 		$64.9K Buy
3,139
+143
+5% +$3.94K ﹤0.01% 1317
2022
Q3 		$78.4K Hold
2,996
– – ﹤0.01% 1167
2022
Q2 		$75.9K Hold
2,996
– – ﹤0.01% 1231
2022
Q1 		$94.6K Sell
2,996
-9,127
-75% -$306K ﹤0.01% 1230
2021
Q4 		$491K Hold
12,123
– – 0.01% 1443
2021
Q3 		$423K Hold
12,123
– – 0.01% 1574
2021
Q2 		$333K Buy
12,123
+846
+8% +$24.2K ﹤0.01% 1779
2021
Q1 		$317K Sell
11,277
-530
-4% -$18.4K ﹤0.01% 1718
2020
Q4 		$307K Hold
11,807
– – ﹤0.01% 1667
2020
Q3 		$202K Buy
11,807
+361
+3% +$8.06K ﹤0.01% 1767
2020
Q2 		$283K Buy
11,446
+276
+2% +$7.45K 0.01% 1581
2020
Q1 		$155K Buy
11,170
+1,255
+13% +$15.6K ﹤0.01% 1746
2019
Q4 		$100K Sell
9,915
-1,631
-14% -$13.7K ﹤0.01% 2333
2019
Q3 		$105K Hold
11,546
– – ﹤0.01% 2277
2019
Q2 		$91.8K Buy
11,546
+1,421
+14% +$14.2K ﹤0.01% 2347
2019
Q1 		$126K Sell
10,125
-1,334
-12% -$14.5K ﹤0.01% 2182
2018
Q4 		$123K Buy
+11,459
New +$134K ﹤0.01% 2134

Other funds holding RCUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RCUS Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Arcus Biosciences (RCUS) in Q2 2024, closing a stake of 2,870 shares — an estimated $54.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RCUS in Q4 2018 and held it in 22 quarters. The position peaked at $491K in Q4 2021. 193 funds tracked by Wall St. Rank hold RCUS as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Arcus Biosciences position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,870 Arcus Biosciences shares in Q2 2024, an estimated $54.2K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Arcus Biosciences in Q4 2018 and held it in 22 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Arcus Biosciences position peaked at $491K in Q4 2021.
  • 193 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.